Status:
RECRUITING
Paradoxical Lucidity in Severe End-Stage Dementia
Lead Sponsor:
NYU Langone Health
Collaborating Sponsors:
National Institute on Aging (NIA)
Conditions:
Dementia
Eligibility:
All Genders
18+ years
Brief Summary
Cognitive decline in dementia is considered irreversible, however episodes of paradoxical lucidity (PL) in severe dementia suggest other mechanisms may be in play. Beyond anecdotal reports of transien...
Eligibility Criteria
Inclusion
- Age \> 18 years
- Advanced (severe) dementia diagnosed using the Global Deterioration Scale (GDS) with a score of 7 or the Palliative Performance Scale (PPS) with a score of less than 30%
- Accepted for hospice care based on the Medicare eligibility guidelines
- No longer being provided with nutrition or fluids
- Anuria (dry diaper) or less than 200cc urine (almost dry diaper) in any 24-hour period
Exclusion
- Cognitive or functional impairment due to a diagnosis other than dementia
- Dementia with a GDS score \<7 (mild, moderate, moderately severe dementia). Please refer to rationale outlined for inclusion criteria 2.
Key Trial Info
Start Date :
June 2 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 31 2026
Estimated Enrollment :
520 Patients enrolled
Trial Details
Trial ID
NCT05234866
Start Date
June 2 2022
End Date
May 31 2026
Last Update
August 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NYU Langone Health
New York, New York, United States, 10016